Skip to main
MLTX
MLTX logo

MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

MoonLake Immunotherapeutics (MLTX) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 53%
Buy 40%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

MoonLake Immunotherapeutics demonstrates a positive outlook due to the robust Phase II data for SLK in the treatment of hidradenitis suppurativa (HS) and other inflammatory conditions, which is anticipated to yield a superior profile in the upcoming Phase III trials. The company's innovative SLK Nanobody, which targets both IL-17A and IL-17F, shows promising efficacy compared to existing treatments like Cosentyx, further supported by strong feedback from key opinion leaders regarding its potential in early-line moderate-to-severe HS. Additionally, the growing market awareness and documented unmet needs in HS, alongside the potential for SLK in other indications, suggest meaningful upside opportunities for MoonLake's stock.

Bears say

MoonLake Immunotherapeutics faces significant risks that contribute to a negative outlook on its stock, primarily revolving around the potential for unexpected safety events and efficacy challenges that could disrupt ongoing clinical trials and lower the likelihood of successful drug development. In addition, the company's recent 4Q24 net loss of $44.2 million reflects its financial strain, further exacerbated by the risks associated with regulatory approvals, which could severely limit revenue generation opportunities. Furthermore, the low placebo response rates observed in clinical trials and the potential lack of differentiation from competitors may hinder market adoption and success in a competitive landscape.

MoonLake Immunotherapeutics (MLTX) has been analyzed by 15 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 40% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MoonLake Immunotherapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MoonLake Immunotherapeutics (MLTX) Forecast

Analysts have given MoonLake Immunotherapeutics (MLTX) a Buy based on their latest research and market trends.

According to 15 analysts, MoonLake Immunotherapeutics (MLTX) has a Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $64.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $64.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MoonLake Immunotherapeutics (MLTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.